VEGFA and cancer: Bevacizumab with chemotherapy contributed to a twofold increase in ATEs (3.8% vs. 1.7%) compared with chemotherapy alone in a combined analysis of five RCTs covering 1745 candidates with three types of malignant tumors, in which VEGF inhibitors were initially identified [88].